<i>De novo</i> isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases
Kebede H. Begna, Jaya Kittur, Jennifer Yui, Naseema Gangat, Mrinal M. Patnaik, Aref Al‐Kali, Michelle A. Elliott, William J. Hogan, Mark R. Litzow, C. Christopher Hook, Alexandra P. Wolanskyj, Matthew T. Howard, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Ayalew Tefferi
Abstract
Institutional database search (1999-2020) for acute myeloid leukaemia (AML) identified 109 cases of myeloid sarcoma (MS), of which 19 were isolated and presented de novo. The latter displayed longer survival (median 78 months), compared to MS with synchronous intramedullary AML (n = 32; median 16 months) and de novo AML without MS (n = 729; median 22 months; P = 0·13). However, the difference in survival was no longer apparent after accounting for bone marrow cytogenetic risk status (P = 0·67). Treatment-induced MS tumour resolution was not affected by the presence of intramedullary disease (P = 0·61). The current study clarifies the prognosis of de novo isolated MS, in the context of AML.